Literature DB >> 22798340

CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.

Nassima Redjimi1, Caroline Raffin, Isabelle Raimbaud, Pascale Pignon, Junko Matsuzaki, Kunle Odunsi, Danila Valmori, Maha Ayyoub.   

Abstract

Antitumor type I T-cell responses involving IFN-γ production are critical to control cancer, but the efficacy of this response is limited by a variety of immunosuppressive mechanisms that promote tumoral immune escape. One critical mechanism involves the accumulation of FOXP3(+) T regulatory cells (Treg), a class of suppressive T cells that prevent excessive tissue destruction caused by unchecked immune responses. Recent studies have revealed that FOXP3(+) Treg include distinct subsets specifically controlling over the corresponding effector subset. In particular, CXCR3(+) Treg have been described as a subset specialized in the control of type I T-cell responses in vivo. Here, we show that CXCR3(+) Treg are highly enriched in human ovarian carcinomas, particularly in solid tumor masses, where they represent the majority of Treg. Tumor-associated CXCR3(+.) Treg coexpress T-bet but do not secrete IFN-γ ex vivo and suppress proliferation and IFN-γ secretion of T effectors. In addition, they coexpress Helios, suggesting that they originate from natural Treg. Finally, we show that the proportion of CXCR3(+) Treg at tumor sites is directly correlated with that of CXCR3(+) T effectors, consistent with expression of CXCR3 ligands. Together, our findings support the concept that natural CXCR3(+) T-bet(+) Treg selectively accumulate in ovarian tumors to control type I T-cell responses, resulting in the collateral limitation of efficient antitumor immunity. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22798340     DOI: 10.1158/0008-5472.CAN-12-0579

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

Review 1.  Roles of regulatory T cells in cancer immunity.

Authors:  Yoshiko Takeuchi; Hiroyoshi Nishikawa
Journal:  Int Immunol       Date:  2016-05-09       Impact factor: 4.823

Review 2.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

Review 3.  Guidance factors orchestrating regulatory T cell positioning in tissues during development, homeostasis, and response.

Authors:  Thorsten R Mempel; Francesco Marangoni
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 4.  Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.

Authors:  Ee Lyn Lim; Klaus Okkenhaug
Journal:  Immunology       Date:  2019-07       Impact factor: 7.397

Review 5.  The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.

Authors:  Andreas Bikfalvi; Clotilde Billottet
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

6.  Tumor Tolerance-Promoting Function of Regulatory T Cells Is Optimized by CD28, but Strictly Dependent on Calcineurin.

Authors:  Francesco Marangoni; Ruan Zhang; Vinidhra Mani; Martin Thelen; Noor J Ali Akbar; Ross D Warner; Tarmo Äijö; Valentina Zappulli; Gustavo J Martinez; Laurence A Turka; Thorsten R Mempel
Journal:  J Immunol       Date:  2018-04-16       Impact factor: 5.422

7.  Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Authors:  Yawara Kawano; Oksana Zavidij; Jihye Park; Michele Moschetta; Katsutoshi Kokubun; Tarek H Mouhieddine; Salomon Manier; Yuji Mishima; Naoka Murakami; Mark Bustoros; Romanos Sklavenitis Pistofidis; Mairead Reidy; Yu J Shen; Mahshid Rahmat; Pavlo Lukyanchykov; Esilida Sula Karreci; Shokichi Tsukamoto; Jiantao Shi; Satoshi Takagi; Daisy Huynh; Antonio Sacco; Yu-Tzu Tai; Marta Chesi; P Leif Bergsagel; Aldo M Roccaro; Jamil Azzi; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 8.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

9.  Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system.

Authors:  Xin Xu; Wael A H Hegazy; Linjie Guo; Xiuhua Gao; Amy N Courtney; Suhrab Kurbanov; Daofeng Liu; Gengwen Tian; Edwin R Manuel; Don J Diamond; Michael Hensel; Leonid S Metelitsa
Journal:  Cancer Res       Date:  2014-09-11       Impact factor: 12.701

10.  Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance.

Authors:  C Tanchot; M Terme; H Pere; T Tran; N Benhamouda; M Strioga; C Banissi; L Galluzzi; G Kroemer; E Tartour
Journal:  Cancer Microenviron       Date:  2012-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.